Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Part D 2014 Draft Call Letter Addresses Automatic Rx Refills, Drug Safety Issues

Executive Summary

CMS instructions to Part D sponsors cite elimination of waste as a reason to require plans to confirm members want a refill. Draft call letter also addresses expanding drug utilization reviews beyond opioids, added controls on compounded drugs.

You may also be interested in...



CMS Doubts Power Of Purse To Stem Public Health Crises With Compounded Drugs

Medicare agency disagrees with HHS Office of Inspector General recommendation that providers be required to identify the source of compounded drugs submitted for Part B payment.

Part D’s Standard Deductible, Copays To Drop In 2014

With dropping drug expenses in Part D, CMS’ annual call letter for Part D drug plans proposes reducing beneficiary expenses for the standard plan in 2014, the first drop since the program began.

CBO Legislative Scores Will Account For Medicare Rx’s Reductions In Other Medical Costs

In a policy change, the Congressional Budget Office, which estimates the impact of legislation on federal spending, will account for pharmaceuticals’ effect on overall medical spending in Medicare for bills that directly affect drug use.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS055135

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel